About the Author Maryke Louw is a chartered physiotherapist with more than 20 years' experience and a Masters Degree in Sports Injury Management

How it helps disc herniation specifically: Upregulates tendon-related growth factors BPC-157 activates the Egr-1 transcription factor, which drives collagen synthesis in fibrous tissue including the annulus fibrosus Promotes angiogenesis increases VEGF expression, improving blood supply to the avascular disc environment Neuroprotective effects multiple rodent studies show BPC-157 accelerates peripheral nerve regeneration and protects against nerve compression injury Systemic anti-inflammatory suppresses pro-inflammatory cytokine cascades without the immunosuppressive side effects of steroids Protocol: Dose: 250500mcg/day subcutaneous injection Injection site: Lower abdomen or closest accessible subQ site to the injury (though systemic distribution means proximity matters less than for localized joint issues) Duration: 68 weeks loading phase, reassess at week 8 Most people notice reduced nerve pain and improved mobility within 24 weeks

David Rosenblum takes a critical, evidence-based look at BPC-157 and other peptides in pain management, examining: The biological rationale behind peptide therapy Preclinical and early human evidence for pain and tissue healing Regulatory status and safety concerns Ethical, legal, and marketing risks for physicians How peptides are currently being incorporated and monetized in pain practices This episode is designed to help clinicians separate science from marketing , and to approach peptide therapies with appropriate caution and professionalism
While natural amylin disappears from the bloodstream within minutes, cagrilintide maintains therapeutic levels for an entire week
Notably, this low dose outperformed even some existing obesity medications at the time, without the troublesome side effects
The peptide accelerates healing through multiple mechanisms